An incidental pulmonary nodule does not have one universal follow-up interval. Establish whether the patient belongs in the incidental-nodule pathway, then identify whether the finding is solid, ground-glass or part-solid, whether there are multiple nodules, and whether prior imaging shows a meaningful change. Size matters, but it is not the whole decision.
This ABIM tutorial uses the Fleischner Society's 2017 recommendations, checked on 27 September 2026, as the named incidental-nodule framework. It does not label the guideline a new 2026 release. All CT reports and patient details below are fictional educational examples, not patient images or recalled examination items.
Check whether the incidental-nodule guideline applies
The Fleischner recommendations address incidentally detected CT nodules in adults aged at least 35. They are not the lung-cancer screening pathway and are not intended for patients with known primary cancer at risk of metastasis or immunocompromised patients at risk of infection. Those boundaries are explicit in the primary guideline, reviewed on 27 September 2026.
The first useful question is therefore how the nodule was found. A screening CT belongs to its screening programme's reporting and management framework. A nodule in someone undergoing cancer staging is not automatically an incidental finding simply because it was unexpected. A new pulmonary lesion during immunosuppression may require an infection-focused assessment rather than routine surveillance.
Do not confuse a stable patient with an eligible patient. Someone can be clinically well and still fall outside the guideline's population. Conversely, an eligible patient may have another symptom requiring investigation that should not be attributed to the nodule without evidence.
Characterise the finding before selecting an interval
Read the report for nodule density, dimensions, location, margins, number and relevant associated findings. Ground-glass and part-solid are not synonyms. In a part-solid lesion, the size and behaviour of the solid component carry information beyond the overall diameter.
Check the quality of the baseline study. Thin-section reconstruction improves characterisation and comparison; a thick-section image can obscure a small solid component. The Fleischner technical recommendations, checked on 27 September 2026, also emphasise reviewing prior imaging and considering differences in technique before declaring growth.
A report saying "small nodule" is insufficient for a precise follow-up decision. The correct response may be to obtain the actual report or radiology clarification rather than guess an interval. In an examination stem, identify which necessary descriptor is supplied and which remains missing.
Combine morphology with the person's risk context
Smoking history, age, previous cancer history, family history, emphysema or fibrosis and the nodule's morphology can affect interpretation. Do not substitute a single label such as smoker for the entire assessment. The question is how the combined context changes the reasonable next step.
The guideline deliberately uses ranges for many follow-up intervals. This allows consideration of morphology, comorbidity and preferences rather than implying that one calendar date is biologically exact. The aim is not maximal scanning for every finding; it is an appropriate balance between detecting important change and avoiding unnecessary investigation.
For larger or suspicious nodules, the choice among further CT, PET/CT, tissue sampling and other specialist evaluation depends on more than size alone. A positive functional scan is not itself a histological diagnosis, and an invasive investigation has its own risks and practical requirements. Do not write "biopsy every nodule over the threshold" as an automatic rule.
Four original CT-report cases
The following fictional reports are constructed to test different decisions. They do not reproduce the guideline's full recommendation table.
| Case | CT finding and context | Main reasoning task |
|---|---|---|
| A | Single smooth 4 mm solid nodule in an otherwise eligible adult with low clinical risk | Decide whether routine follow-up is needed |
| B | Single 7 mm solid nodule in an eligible adult with substantial smoking history | Select surveillance using the appropriate solid-nodule pathway |
| C | Persistent 9 mm ground-glass nodule without a described solid component | Recognise that the subsolid pathway differs |
| D | A part-solid lesion whose solid component has increased on comparable scans | Reassess concern rather than repeat the previous routine plan |
Case A: do not invent benefit from routine surveillance. Under the Fleischner 2017 recommendations, checked on 27 September 2026, a single solid nodule below 6 mm in a low-risk eligible adult does not require routine follow-up. The important assumptions are the patient's eligibility, the solid morphology, the reliable measurement and the absence of a separate concerning clinical context.
A tempting wrong answer is to obtain repeated CT examinations simply because any nodule could theoretically be malignant. Another is to apply this conclusion to a patient with known cancer or immunosuppression. The same diameter does not make those cases equivalent.
Case B: use the solid-nodule surveillance range. For an eligible higher-risk patient with a solitary solid nodule measuring 6 to 8 mm, the named guideline recommends CT at 6 to 12 months and again at 18 to 24 months. These are the published 2017 ranges as checked on 27 September 2026, not an asserted ABIM scoring rule or a forecast of when a future question will adopt a recommendation.
The learner should explain why immediate tissue sampling is not automatically the next step for this fictional 7 mm finding. They should also identify the need to compare prior scans and to revisit the plan if the morphology or clinical circumstances become more concerning.
Case C: do not use a short solid-nodule stopping rule. A persistent ground-glass lesion is not managed as though it were an equally sized solid nodule. The Fleischner subsolid recommendations, reviewed on 27 September 2026, use longer surveillance for an appropriate persistent ground-glass finding of this size, including an initial persistence check and subsequent follow-up extending to five years.
The wrong inference is that stability over a brief period proves that no further review is needed. The relevant questions are whether it is genuinely pure ground-glass, whether the comparison is technically reliable and whether any solid component or other suspicious change has emerged.
Case D: changed morphology changes the question. In this fictional timeline, the overall diameter appears similar but the solid component is larger on comparable scans. The candidate should not focus only on total size. Increasing solidity can change concern and the need for specialist evaluation, as discussed in the primary Fleischner recommendations.
The next decision requires the actual measurements, morphology, risk context and appropriate multidisciplinary input. Repeating the old surveillance interval without acknowledging the new finding would carry an earlier assumption forward after the evidence has changed.
Understand multiple nodules and the dominant concern
With multiple nodules, do not assume that the largest one is necessarily the most suspicious. Morphology and change may identify a smaller lesion as the finding that governs the next step. The rest of the lungs and the clinical context still matter.
A collection of small nodules in an otherwise eligible person is different from new nodules during an active infection or cancer assessment. The phrase "multiple nodules" is a description, not a diagnosis of metastases. State the hypothesis and what supports it rather than turning distribution alone into certainty.
When comparing guidelines, name the framework used. Screening recommendations, incidental-nodule recommendations and cancer-specific pathways answer different questions. Apparent disagreement may reflect a different population rather than an error in one source.
Make surveillance an owned clinical plan
A follow-up recommendation is incomplete until someone is responsible for arranging, reviewing and acting on the result. Document the original finding, the source and rationale for the chosen interval, the comparison needed and the circumstances that should trigger earlier clinical review.
A fictional explanation to a patient might be: "The scan has shown a small finding that does not currently require an immediate invasive test. The follow-up plan depends on its appearance and your overall circumstances. We will compare the next scan with this one, and the responsible team will review any change rather than leave the result unassigned."
This is an example of explaining a plan, not a reassurance that the lesion is definitely benign. Avoid both alarmist language and unsupported certainty. The patient should understand what is known, what remains uncertain and why the proposed next step is proportionate.
Turn the cases into an ABIM revision exercise
For each report, hide the answer and write eligibility, morphology, risk context, comparison and next action. Then change one fact: make the CT a screening examination, introduce known cancer, change solid to part-solid, or provide a new scan showing growth. Explain why the original answer may no longer apply.
Use a current source to settle a disagreement, not a remembered bank explanation alone. Per iatroX product information, September 2026, its question banks and Socratic Tutor support targeted reasoning practice. They do not replace review of the actual CT, a radiologist's interpretation or a clinically appropriate nodule pathway.
Frequently asked questions
Do Fleischner recommendations apply to lung-cancer screening CTs?
No. Screening findings should be managed through the relevant screening framework rather than automatically assigned an incidental-nodule interval.
Can I choose follow-up from nodule diameter alone?
No. Eligibility, density, morphology, number, growth and patient context can all change the decision.
Does a stable overall diameter mean a part-solid nodule is unchanged?
Not necessarily. A change in the solid component may be important even when the overall measurement appears similar.
Practise matching imaging findings to the next clinical decision →